CVT -PVT Covid-19: come AstraZeneca ha perso la guerra di PR del vaccino

La quantità di cattiva stampa che ha non è basata sulla scienza” Sembra completamente sproporzionato o infondato

https://www.bmj.com/content/373/bmj.n921?=&utm_source=adestra&utm_medium=email&utm_campaign=usage&utm_content=daily&utm_term=text

 

https://www.aifa.gov.it/documents/20142/1315190/Rapporto_sorveglianza_vaccini_COVID-19_3.pdf

https://osf.io/a9jdq/

The incidence of cerebral  venous thrombosis  (CVT) was:

– 39.0 per million people after COVID-19 diagnosis
– 0.0 per million people after influenza
– 4.1 per million people after receiving BNT162b2 [Pfizer] or 
mRNA-1273 [Moderna] vaccine
– 5 per million people after receiving ChAdOx1 nCoV-19 [AstraZeneca] vaccine*


The incidence of portal vein thrombosis (PVT) was:

– 436 per million people after COVID-19 diagnosis
– 98.4 per million people after influenza
– 44.9 per million people after receiving BNT162b2 [Pfizer] or 
mRNA-1273 [Moderna] vaccine
– 1.6 per million people after receiving ChAdOx1 nCoV-19 [AstraZeneca] 
vaccine*

*Dati EMA, non provenienti dal database americano studiato per 
calcolare l’incidenza di trombosi da COVID, influenza e vaccini 
Pfizer/Moderna.

In summary, COVID-19 is associated with a markedly increased incidence of CVT compared to the general population,patients with influenza, and people who have received BNT162b2 or mRNA-1273vaccinesThe risk with COVID19 also appears greater than with ChAdOx1 nCoV19, although as
noted this conclusion is tentative.The rarity of CVT in all populatio
ns means that larger sample sizes are required  to confirm the
results, and complementary study designs are needed to aid interpretation.Nevertheless, the current data highlight the risk of serious thrombotic events in COVID19, and can help contextualize and inform debate about the risk benefit ratio for current COVID 19 vaccines